Novo Nordisk AS
NVO
Company Profile
Business description
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
77,406
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,637.80 | 12.90 | 0.15% |
| CAC 40 | 7,848.23 | 60.13 | 0.77% |
| DAX 40 | 24,140.14 | 101.95 | 0.42% |
| Dow JONES (US) | 42,098.70 | 244.95 | -0.58% |
| FTSE 100 | 8,725.87 | 0.14 | -0.00% |
| HKSE | 23,573.38 | 315.07 | 1.35% |
| NASDAQ | 19,100.94 | 98.22 | -0.51% |
| Nikkei 225 | 38,432.98 | 710.58 | 1.88% |
| NZX 50 Index | 12,281.31 | 80.95 | -0.65% |
| S&P 500 | 5,888.55 | 32.99 | -0.56% |
| S&P/ASX 200 | 8,409.80 | 12.90 | 0.15% |
| SSE Composite Index | 3,363.45 | 23.51 | 0.70% |